Consensus Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Market Closed - Nasdaq 04:00:00 2024-05-17 pm EDT 5-day change 1st Jan Change
9.57 USD +0.74% Intraday chart for Amicus Therapeutics, Inc. +3.68% -32.56%

Evolution of the average Target Price on Amicus Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b0e91c27c93e7baf8a876128.tyfLVybnqjEREUyouKjIKb5yRKIFpqTccBMBK-E3U4Q.hlf-ZkSrm1JiPDT66MKNSvIAcsNk0dPsSV5PH5EAF93ZH5EFbpb7dml4CQ~45fd546ea5b8a221565092e99a3f484e
Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target MT
UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating MT
JPMorgan Adjusts Price Target on Amicus Therapeutics to $19 From $21, Maintains Overweight Rating MT
Morgan Stanley Upgrades Amicus Therapeutics to Overweight From Equalweight, Raises Price Target to $20 From $15 MT
Morgan Stanley Adjusts Price Target on Amicus Therapeutics to $15 From $14, Maintains Equalweight Rating MT
Morgan Stanley Trims Amicus Therapeutics' Price Target to $14 From $15, Keeps Equalweight Rating MT
UBS Ups Price Target on Amicus Therapeutics to $20 From $19, Maintains Buy Rating MT
JPMorgan Raises Price Target on Amicus Therapeutics to $19 From $17, Maintains Overweight Rating MT
UBS Adjusts Amicus Therapeutics Price Target to $19 From $17, Maintains Buy Rating MT
BofA Securities Adjusts Price Target on Amicus Therapeutics to $17 From $16, Maintains Buy Rating MT
Goldman Sachs Adjusts Amicus Therapeutics' Price Target to $11 From $10, Keeps Neutral Rating MT
UBS Adjusts Amicus Therapeutics Price Target to $17 From $15, Maintains Buy Rating MT
BTIG Adjusts Price Target on Amicus Therapeutics to $16 From $14, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Amicus Therapeutics to $15 From $14, Maintains Equalweight Rating MT
Berenberg Bank Adjusts Amicus Therapeutics Price Target to $12 From $11 on Improved Confidence in AT-GAA, Maintains Hold Rating MT
Morgan Stanley Initiates Amicus Therapeutics at Equalweight Rating With $14 Price Target MT
Goldman Sachs Reinstates Amicus Therapeutics at Neutral With $11 Price Target MT
Berenberg Bank Adjusts Amicus Therapeutics' Price Target to $12 From $14, Maintain Hold Rating MT
SVB Leerink Upgrades Amicus Therapeutics to Outperform From Market Perform; Price Target is $16 MT
Cantor Fitzgerald Adjusts Amicus Therapeutics' Price Target to $15 from $16, Keeps Overweight Rating MT
Stifel Lifts Amicus Therapeutics to Buy From Hold, Price Target to $16 From $12 MT
ANALYSTS' OPINIONS OF THE DAY : Admiral, Dollar Tree, EasyJet, Netflix, Planet Fitness... Our Logo
AMICUS THERAPEUTICS : SVB Leerink Adjusts Amicus Therapeutics PT to $12 from $13, Maintains Market Perform Rating MT
AMICUS THERAPEUTICS : JPMorgan Upgrades Amicus Therapeutics to Overweight From Neutral, Price Target at $16 MT
AMICUS THERAPEUTICS : Chardan Suspends Coverage on Akero Therapeutics at Neutral Rating With $12.50 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
9.57 USD
Average target price
17.3 USD
Spread / Average Target
+80.77%
High Price Target
21 USD
Spread / Highest target
+119.44%
Low Price Target
13 USD
Spread / Lowest Target
+35.84%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Amicus Therapeutics, Inc.

Guggenheim
UBS
JPMorgan Chase
Morgan Stanley
BofA Securities
Goldman Sachs
BTIG
Berenberg Bank
SVB Leerink
Cantor Fitzgerald
Stifel Nicolaus
Chardan
Needham & Co.
J.P. Morgan Chase
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
  1. Stock Market
  2. Equities
  3. FOLD Stock
  4. Consensus Amicus Therapeutics, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW